AR041297A1 - Derivados de 4-pirrolidino- fenil- bencil eter - Google Patents
Derivados de 4-pirrolidino- fenil- bencil eterInfo
- Publication number
- AR041297A1 AR041297A1 ARP030103383A ARP030103383A AR041297A1 AR 041297 A1 AR041297 A1 AR 041297A1 AR P030103383 A ARP030103383 A AR P030103383A AR P030103383 A ARP030103383 A AR P030103383A AR 041297 A1 AR041297 A1 AR 041297A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- hydrogen
- derivatives
- pirrolidino
- Prior art date
Links
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Procesos para su preparación, composiciones farmacéuticas que comprenden dichos derivados, y su uso en la prevención y tratamiento de enfermedades, por ejemplo que están mediadas por inhibidores de monoamino oxidasa B, en particular enfermedad deAlzheimer o demencia senil. Reivindicación 1: Un compuesto de la fórmula (1), en donde: X-Y es -CH2-CH2-, -CH=CH- o -CH2-O-; R1, R1,1 y R1,2 independientemente el uno del otro están seleccionados del grupo consistente en hidrógeno, halógeno, ciano,alquilo (C1-6), halógeno-alquilo (C1-6), alcoxilo (C1-6) o halógeno-alcoxilo (C1-6); R21, R22 y R23 independientemente el uno del otro están seleccionados del grupo consistente en hidrógeno y halógeno; R24 es hidrógeno, halógeno o metilo; R3 eshidrógeno; R4 es -CONHR5, -CN o -NHR6; R5 es hidrógeno o alquilo (C1-3); y R6 es -CO-H, -CO-alquilo (C1-6), -CO-halógeno-alquilo (C1-3), -CO-O-alquilo (C1-3), -CO-NH2 o -SO2-alquilo (C1-6); así como isómeros individuales, mezclas racémicas o noracémicas de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02021319 | 2002-09-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041297A1 true AR041297A1 (es) | 2005-05-11 |
Family
ID=32010924
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103385A AR041299A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de pirrolidona como inhibidores de maob |
| ARP030103383A AR041297A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de 4-pirrolidino- fenil- bencil eter |
| ARP030103384A AR041298A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de pirrolidona como inhibidores de maob |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103385A AR041299A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de pirrolidona como inhibidores de maob |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103384A AR041298A1 (es) | 2002-09-20 | 2003-09-18 | Derivados de pirrolidona como inhibidores de maob |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7151111B2 (es) |
| EP (3) | EP1542970B1 (es) |
| JP (3) | JP4335141B2 (es) |
| KR (3) | KR100681586B1 (es) |
| CN (3) | CN100383118C (es) |
| AR (3) | AR041299A1 (es) |
| AT (2) | ATE472530T1 (es) |
| AU (3) | AU2003270213B8 (es) |
| BR (4) | BRPI0314631B1 (es) |
| CA (3) | CA2498785C (es) |
| CY (1) | CY1110745T1 (es) |
| DE (2) | DE60333202D1 (es) |
| DK (1) | DK1542970T3 (es) |
| ES (2) | ES2338646T3 (es) |
| GT (3) | GT200300206A (es) |
| HR (3) | HRP20050261A2 (es) |
| JO (2) | JO2604B1 (es) |
| MX (3) | MXPA05002878A (es) |
| MY (3) | MY134480A (es) |
| NO (3) | NO330012B1 (es) |
| NZ (3) | NZ538048A (es) |
| PA (3) | PA8583001A1 (es) |
| PE (3) | PE20050077A1 (es) |
| PL (3) | PL216030B1 (es) |
| PT (1) | PT1542970E (es) |
| RU (3) | RU2323209C2 (es) |
| SI (1) | SI1542970T1 (es) |
| TW (3) | TWI286132B (es) |
| UY (3) | UY27990A1 (es) |
| WO (3) | WO2004026827A1 (es) |
| ZA (3) | ZA200501137B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY134480A (en) * | 2002-09-20 | 2007-12-31 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| GB0314373D0 (en) | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
| RU2378270C2 (ru) * | 2004-08-02 | 2010-01-10 | Ф. Хоффманн-Ля Рош Аг | Бензилокси-производные в качестве ингибиторов моноаминоксидазы b |
| KR100845366B1 (ko) * | 2004-08-02 | 2008-07-09 | 에프. 호프만-라 로슈 아게 | 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체 |
| WO2006089674A2 (en) | 2005-02-25 | 2006-08-31 | F.Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
| ES2314877T3 (es) * | 2005-03-15 | 2009-03-16 | F. Hoffmann-La Roche Ag | Metodo para preparar derivados de eter-4-pirrolidino-fenilbencilico enantiomericamente puros. |
| US7501528B2 (en) * | 2005-03-15 | 2009-03-10 | Hoffmann-La Roche Inc. | Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| DE602006015215D1 (de) * | 2005-10-10 | 2010-08-12 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| US8372380B2 (en) * | 2007-03-30 | 2013-02-12 | The Regents Of The University Of California | In vivo imaging of sulfotransferases |
| KR101220182B1 (ko) * | 2009-02-25 | 2013-01-11 | 에스케이바이오팜 주식회사 | 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법 |
| CZ304053B6 (cs) * | 2011-08-22 | 2013-09-04 | Farmak, A. S. | Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu |
| KR102018284B1 (ko) * | 2013-02-28 | 2019-09-05 | 삼성디스플레이 주식회사 | 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치 |
| KR20150127172A (ko) | 2013-03-14 | 2015-11-16 | 다트 뉴로사이언스 (케이만) 엘티디. | Mao 억제제로서 치환된 나프티리딘 및 퀴놀린 화합물 |
| CZ305213B6 (cs) * | 2013-04-29 | 2015-06-10 | Farmak, A. S. | Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy |
| WO2015063001A1 (en) | 2013-10-29 | 2015-05-07 | F. Hoffmann-La Roche Ag | Crystalline forms of a pyrrolidone derivative useful in the treatment of alzheimer's disease and preparation thereof |
| US10421716B2 (en) | 2014-12-23 | 2019-09-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| JP2018509400A (ja) * | 2015-03-27 | 2018-04-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | セムブラギリンを含む医薬製剤 |
| US11365194B2 (en) | 2017-09-27 | 2022-06-21 | Kagoshima University | Analgesic drug using PAC1 receptor antagonistic drug |
| KR20200061381A (ko) | 2017-10-05 | 2020-06-02 | 바이오젠 인크. | 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정 |
| CN108299272B (zh) * | 2018-01-31 | 2019-10-18 | 福州大学 | 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法 |
| EP3762364B1 (en) * | 2018-03-08 | 2023-08-23 | Sunshine Lake Pharma Co., Ltd. | Pyrrolidineamide derivatives and uses thereof |
| JP7501920B2 (ja) | 2019-02-27 | 2024-06-18 | 国立大学法人 鹿児島大学 | Ｐａｃ１受容体拮抗薬を用いた鎮痒薬 |
| US12458643B2 (en) | 2020-05-08 | 2025-11-04 | Kagoshima University | Antidepressant/anxiolytic drug in which PAC1 receptor antagonist is used |
| CN112851561A (zh) * | 2021-01-29 | 2021-05-28 | 南京艾美斐生物医药科技有限公司 | 一种nr6a1蛋白受体抑制剂及其制备和应用 |
| WO2022268520A1 (de) | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen. |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4348393A (en) * | 1978-06-09 | 1982-09-07 | Delalande S.A. | N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones |
| FR2500831A1 (fr) | 1981-02-27 | 1982-09-03 | Delalande Sa | Nouvelles n-aryl-oxazolidinones et -pyrrolidinones |
| EP0393607B1 (en) | 1989-04-19 | 1996-02-21 | Otsuka Pharmaceutical Co., Ltd. | Phenylcarboxylic acid derivatives having a hetero ring |
| AU688102B2 (en) * | 1994-08-30 | 1998-03-05 | Sankyo Company Limited | Isoxazoles |
| US5679715A (en) | 1995-06-07 | 1997-10-21 | Harris; Richard Y. | Method for treating multiple sclerosis |
| WO1997033572A1 (en) | 1996-03-15 | 1997-09-18 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
| US5683404A (en) * | 1996-06-05 | 1997-11-04 | Metagen, Llc | Clamp and method for its use |
| DE19841895A1 (de) | 1998-09-11 | 2000-03-23 | Degussa | Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung |
| EP1165546A2 (en) * | 1999-04-02 | 2002-01-02 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| AU1359801A (en) | 1999-11-05 | 2001-06-06 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
| DE60113965T2 (de) * | 2000-02-10 | 2006-07-06 | Potencia Medical Ag | Behandlung der harninkontinenz mit kabelloser energiezufuhr |
| ATE296071T1 (de) * | 2000-02-14 | 2005-06-15 | Potencia Medical Ag | Penisprothese |
| MY134480A (en) * | 2002-09-20 | 2007-12-31 | Hoffmann La Roche | 4-pyrrolidino-phenyl-benzyl ether derivatives |
| US20040267292A1 (en) * | 2003-06-27 | 2004-12-30 | Byrum Randal T. | Implantable band with transverse attachment mechanism |
| US20040267291A1 (en) * | 2003-06-27 | 2004-12-30 | Byrum Randal T. | Implantable band with non-mechanical attachment mechanism |
-
2003
- 2003-09-17 MY MYPI20033545A patent/MY134480A/en unknown
- 2003-09-17 PE PE2003000952A patent/PE20050077A1/es not_active Application Discontinuation
- 2003-09-17 TW TW092125618A patent/TWI286132B/zh not_active IP Right Cessation
- 2003-09-17 PA PA20038583001A patent/PA8583001A1/es unknown
- 2003-09-18 GT GT200300206A patent/GT200300206A/es unknown
- 2003-09-18 UY UY27990A patent/UY27990A1/es not_active Application Discontinuation
- 2003-09-18 WO PCT/EP2003/010384 patent/WO2004026827A1/en not_active Ceased
- 2003-09-18 HR HR20050261A patent/HRP20050261A2/hr not_active Application Discontinuation
- 2003-09-18 GT GT200300205A patent/GT200300205A/es unknown
- 2003-09-18 EP EP03750564A patent/EP1542970B1/en not_active Expired - Lifetime
- 2003-09-18 RU RU2005111969/04A patent/RU2323209C2/ru not_active IP Right Cessation
- 2003-09-18 US US10/667,087 patent/US7151111B2/en not_active Expired - Lifetime
- 2003-09-18 JP JP2004537120A patent/JP4335141B2/ja not_active Expired - Fee Related
- 2003-09-18 CN CNB038219522A patent/CN100383118C/zh not_active Expired - Fee Related
- 2003-09-18 HR HRP20050263AA patent/HRP20050263B1/hr not_active IP Right Cessation
- 2003-09-18 HR HR20050262A patent/HRP20050262A2/xx not_active Application Discontinuation
- 2003-09-18 US US10/667,088 patent/US7037935B2/en not_active Expired - Fee Related
- 2003-09-18 PT PT03750564T patent/PT1542970E/pt unknown
- 2003-09-18 US US10/666,594 patent/US7235581B2/en not_active Expired - Fee Related
- 2003-09-18 AR ARP030103385A patent/AR041299A1/es not_active Application Discontinuation
- 2003-09-18 KR KR1020057004699A patent/KR100681586B1/ko not_active Expired - Fee Related
- 2003-09-18 BR BRPI0314631-6A patent/BRPI0314631B1/pt unknown
- 2003-09-18 BR BR0314299-0A patent/BR0314299A/pt active Search and Examination
- 2003-09-18 PA PA20038583601A patent/PA8583601A1/es unknown
- 2003-09-18 EP EP03757866A patent/EP1542971A1/en not_active Withdrawn
- 2003-09-18 RU RU2005111968/04A patent/RU2336268C2/ru not_active IP Right Cessation
- 2003-09-18 MX MXPA05002878A patent/MXPA05002878A/es active IP Right Grant
- 2003-09-18 MY MYPI20033559A patent/MY135696A/en unknown
- 2003-09-18 AU AU2003270213A patent/AU2003270213B8/en not_active Ceased
- 2003-09-18 MY MYPI20033558A patent/MY133332A/en unknown
- 2003-09-18 CA CA2498785A patent/CA2498785C/en not_active Expired - Fee Related
- 2003-09-18 BR BR0314314-7A patent/BR0314314A/pt not_active IP Right Cessation
- 2003-09-18 NZ NZ538048A patent/NZ538048A/en not_active IP Right Cessation
- 2003-09-18 PE PE2003000958A patent/PE20050079A1/es active IP Right Grant
- 2003-09-18 WO PCT/EP2003/010356 patent/WO2004026825A1/en not_active Ceased
- 2003-09-18 CN CNB038217678A patent/CN100400509C/zh not_active Expired - Fee Related
- 2003-09-18 AT AT03750564T patent/ATE472530T1/de active
- 2003-09-18 EP EP03748052A patent/EP1542969B1/en not_active Expired - Lifetime
- 2003-09-18 TW TW092125735A patent/TWI337604B/zh not_active IP Right Cessation
- 2003-09-18 MX MXPA05002880A patent/MXPA05002880A/es active IP Right Grant
- 2003-09-18 JP JP2004537119A patent/JP4335140B2/ja not_active Expired - Fee Related
- 2003-09-18 RU RU2005111974/04A patent/RU2336267C2/ru not_active IP Right Cessation
- 2003-09-18 SI SI200331830T patent/SI1542970T1/sl unknown
- 2003-09-18 ES ES03748052T patent/ES2338646T3/es not_active Expired - Lifetime
- 2003-09-18 CA CA002498335A patent/CA2498335A1/en not_active Abandoned
- 2003-09-18 KR KR1020057004683A patent/KR100676015B1/ko not_active Expired - Fee Related
- 2003-09-18 NZ NZ538049A patent/NZ538049A/en unknown
- 2003-09-18 JO JO2003115A patent/JO2604B1/en active
- 2003-09-18 DE DE60333202T patent/DE60333202D1/de not_active Expired - Lifetime
- 2003-09-18 PA PA20038583501A patent/PA8583501A1/es unknown
- 2003-09-18 AU AU2003273901A patent/AU2003273901B2/en not_active Ceased
- 2003-09-18 UY UY27991A patent/UY27991A1/es not_active Application Discontinuation
- 2003-09-18 AU AU2003267381A patent/AU2003267381B2/en not_active Ceased
- 2003-09-18 NZ NZ538046A patent/NZ538046A/en not_active IP Right Cessation
- 2003-09-18 WO PCT/EP2003/010383 patent/WO2004026826A1/en not_active Ceased
- 2003-09-18 PE PE2003000956A patent/PE20050078A1/es not_active Application Discontinuation
- 2003-09-18 PL PL376021A patent/PL216030B1/pl unknown
- 2003-09-18 AT AT03748052T patent/ATE459601T1/de active
- 2003-09-18 ES ES03750564T patent/ES2344557T3/es not_active Expired - Lifetime
- 2003-09-18 CN CNB038212560A patent/CN100503562C/zh not_active Expired - Fee Related
- 2003-09-18 KR KR1020057004718A patent/KR100676014B1/ko not_active Expired - Fee Related
- 2003-09-18 GT GT200300204A patent/GT200300204A/es unknown
- 2003-09-18 AR ARP030103383A patent/AR041297A1/es unknown
- 2003-09-18 BR BR0314631-6A patent/BR0314631A/pt not_active IP Right Cessation
- 2003-09-18 MX MXPA05002881A patent/MXPA05002881A/es active IP Right Grant
- 2003-09-18 JO JO2003116A patent/JO2605B1/en active
- 2003-09-18 JP JP2004537121A patent/JP4335142B2/ja not_active Expired - Fee Related
- 2003-09-18 PL PL03376018A patent/PL376018A1/xx not_active Application Discontinuation
- 2003-09-18 DK DK03750564.1T patent/DK1542970T3/da active
- 2003-09-18 DE DE60331559T patent/DE60331559D1/de not_active Expired - Lifetime
- 2003-09-18 CA CA2496756A patent/CA2496756C/en not_active Expired - Fee Related
- 2003-09-18 AR ARP030103384A patent/AR041298A1/es unknown
- 2003-09-18 TW TW092125746A patent/TWI331994B/zh not_active IP Right Cessation
- 2003-09-18 PL PL03376019A patent/PL376019A1/xx not_active Application Discontinuation
- 2003-09-19 UY UY27993A patent/UY27993A1/es not_active Application Discontinuation
-
2005
- 2005-02-08 NO NO20050665A patent/NO330012B1/no not_active IP Right Cessation
- 2005-02-08 NO NO20050652A patent/NO329754B1/no not_active IP Right Cessation
- 2005-02-08 ZA ZA200501137A patent/ZA200501137B/xx unknown
- 2005-02-09 NO NO20050701A patent/NO20050701L/no not_active Application Discontinuation
- 2005-02-14 ZA ZA200501311A patent/ZA200501311B/en unknown
- 2005-02-22 ZA ZA200501557A patent/ZA200501557B/xx unknown
-
2006
- 2006-01-05 US US11/325,747 patent/US7122562B2/en not_active Expired - Fee Related
-
2010
- 2010-08-20 CY CY20101100770T patent/CY1110745T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041297A1 (es) | Derivados de 4-pirrolidino- fenil- bencil eter | |
| NO20063928L (no) | Substituerte kinolinforbindelser | |
| AR040489A1 (es) | Compuestos derivados de 3-fenil-propionamido, 3-fenil-acrilamido y 3-fenil-propinamido, su uso para la elaboracion de medicamentos, un proceso para elaborar los compuestos y medicamentos que los contienen | |
| NO20080456L (no) | Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer | |
| ATE440087T1 (de) | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen | |
| HRP20041042A2 (hr) | Novi supstituirani derivati sulfamata kao antikonvulzivi | |
| CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| SE0403171D0 (sv) | New compounds | |
| ATE512961T1 (de) | Amorphes nebivolol hydrochlorid und seine herstellung | |
| CL2003002565A1 (es) | Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci | |
| UY27842A1 (es) | Fluorobenzamidas | |
| AR040133A1 (es) | Derivados de n-acilamino bencil eter | |
| AR039651A1 (es) | Derivados de isoquinolina | |
| BRPI0407968A (pt) | derivados de oxamida úteis como inibidores de raf-quinase | |
| EA200500133A1 (ru) | Производные пирролидина в качестве антагонистов окситоцина | |
| NO20060383L (no) | Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister | |
| AR038342A1 (es) | Derivados piridin-amido | |
| NO20070972L (no) | Benzyloksyderivater som MAOB-inhibitorer | |
| DE602004025935D1 (de) | Histondeacetylaseinhibitor und verfahren zu dessen herstellung | |
| DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
| UY28145A1 (es) | Nuevos compuestos farmaceuticos | |
| AR040788A1 (es) | 2,3- dihidro -isoindol-1-onas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |